Corticosteroid use

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was associated with a significantly higher risk of behavior problems among males with dystrophinopathy, with the hazard of behavior problems being 2.4 times higher during years in w

Effect: adverse; HR=2.35; CI: 95%CI=1.75,3.16

Corticosteroid use was not significantly associated with ADHD among males with dystrophinopathy, suggesting that ADHD may be part of the dystrophinopathy neurocognitive phenotype independent of treatm

Effect: null

Corticosteroid use was not significantly associated with ADHD among males with dystrophinopathy, suggesting that ADHD may be part of the dystrophinopathy neurocognitive phenotype independent of treatm

Effect: null

Corticosteroid use was not significantly associated with ADHD among males with dystrophinopathy, suggesting that ADHD may be part of the dystrophinopathy neurocognitive phenotype independent of treatm

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null

Corticosteroid use was not significantly associated with depressed mood among males with dystrophinopathy in the primary analysis.

Effect: null